Skip to main content
CIThe Cigna GroupSell5.9·$292.88-1.72%
Open full analysis

The Cigna Group (CI) Stock Analysis

Breakout setup

SellModerate Confidence

Healthcare · Healthcare Plans

Sell if holding. Engine safety override at $292.88: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: Elevated put/call ratio: 8.11; Below-average business quality.

The Cigna Group runs two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, care services) and Cigna Healthcare (commercial medical plans, international health), serving 185 million customer relationships. Revenue comes from pharmacy processing... Read more

$292.88+4.8% A.UpsideScore 5.9/10#2 of 11 Healthcare Plans
QualityF-score7 / 9FCF yield8.78%
IncomeYield2.09%(5y avg 1.68%)Payout24.36%sustainable
Stop $279.44Target $306.82(analyst − 10%)A.R:R 0.6:1
Analyst target$340.92+16.4%24 analysts
$306.82our TP
$292.88price
$340.92mean
$400

Sell if holding. Engine safety override at $292.88: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: Elevated put/call ratio: 8.11; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Score 5.9/10, moderate confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

10-K grounded · weekly refresh

About The Cigna Group

About The Cigna Group

The Cigna Group served more than 185 million customer relationships across more than 30 markets and jurisdictions as of December 31, 2025, through two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, and care services) and Cigna Healthcare (commercial medical plans and international health). On March 19, 2025, the company completed the sale of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plan, and supplemental benefits businesses to Health Care Service Corporation. Individual and family plan offerings are currently available in 11 states.

Evernorth Health Services — anchored by the Express Scripts pharmacy benefit brand and Accredo Specialty Pharmacy (35 licensed pharmacies) — earns fees from processing pharmacy benefit claims, managing drug formularies and rebates, and distributing specialty pharmaceuticals through CuraScript SD (four distribution centers). Three clients each drive significant Evernorth revenues: Centene Corporation under a multiyear agreement from January 1, 2024; Prime Therapeutics; and TRICARE, the U.S. Department of Defense military health care program. Evernorth sources roughly half of pharmaceutical purchases from a single wholesaler, with backup contracts available from other wholesalers. Cigna Healthcare generates premiums and ASO fees from employer medical plans, individual and family plans, and international health coverage; ASO arrangements represented approximately 32% of 2025 Cigna Healthcare segment revenues, covering 79% of Cigna Healthcare medical customers. The 10 largest retail pharmacy chains represent approximately 47% of total stores in Cigna's largest pharmacy network.

Show full overview

Evernorth announced a rebate-free pharmacy benefit model that Cigna Healthcare's fully insured customers plan to adopt from 2027, with all Evernorth Health Services clients intending to transition to the new standard model from 2028. The Inflation Reduction Act granted CMS authority to negotiate prices for high-cost Medicare Part D and Part B drugs; the 10-K notes drug companies may adjust broader market pricing strategies in response, which could affect formulary rebate economics. If pharmaceutical manufacturers reduce rebates during the transition to the rebate-free model, pharmacy benefit segment margins could be affected, depending on how quickly the new model gains client adoption.

See also: Healthcare · Healthcare Plans

From The Cigna Group's most recent 10-K filing, extracted June 9, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-15

Recent Developments — The Cigna Group

Generated 2026-06-15T18:11:46Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Jul 30, 202645d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.9 < 4.0)

Key Metrics

P/E (TTM)11.9
P/E (Fwd)8.9
Mkt Cap$78.8B
EV/EBITDA7.6
Profit Mgn2.3%
ROE16.3%
Rev Growth4.6%
Beta0.30
Dividend2.09%
Rating analysts33

Quality Signals

Piotroski F7/9

Options Flow

P/C8.11bearish
IV37%normal
Max Pain$140-52.2% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMSupplierone wholesaler
    10-K Item 1: 'Evernorth Health Services uses one wholesaler for approximately half of our pharmaceutical purchases'
  • MEDIUMCustomerCentene Corporation
    10-K Item 1: 'three clients that each drive significant revenues ... Express Scripts and Centene Corporation ("Centene") have a multiyear agreement'
  • MEDIUMCustomerPrime Therapeutics
    10-K Item 1: 'three clients that each drive significant revenues ... Express Scripts and Prime Therapeutics LLC ("Prime") have agreements'
  • MEDIUMCustomerTRICARE
    10-K Item 1: 'three clients that each drive significant revenues ... The Department of War (previously the Department of Defense) TRICARE® is the military health care program'
  • MEDIUMcounterparty10 largest retail pharmacy chains
    10-K Item 1A: 'The 10 largest retail pharmacy chains represent approximately 47% of the total number of stores in our largest network'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Net Margin
1.1
Operating Margin
2.2
Roa
3.2
Current Ratio
3.3
Moat
5.0
Roe
5.4
Fcf Quality
7.5
Piotroski F
7.8
No competitive moatStrong Piotroski F-Score: 7/9
GatesA.R:R 0.6 < 1.5@spotMomentum 6.8>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 45d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Moderate
RSI
62 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $268.87Resistance $299.27

Price Targets

$279
$307
A.Upside+4.8%
A.R:R0.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.9 < 4.0)
! asymmetry at 0.6 (below the engine's 1.5 threshold)@spot

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-30 (45d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CI stock a buy right now?

Sell if holding. Engine safety override at $292.88: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: Elevated put/call ratio: 8.11; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Prior stop was $279.44. Score 5.9/10, moderate confidence.

What is the CI stock price target?

Take-profit target: $306.82 (+4.8% upside). Prior stop was $279.44. Stop-loss: $279.44.

What are the risks of investing in CI?

Quality below floor (3.9 < 4.0).

Is CI overvalued or undervalued?

The Cigna Group trades at a P/E of 11.9 (forward 8.9). TrendMatrix value score: 7.9/10. Verdict: Sell.

What do analysts say about CI?

33 analysts cover CI with a consensus score of 4.2/5. Average price target: $341.

What does The Cigna Group do?The Cigna Group runs two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, care...

The Cigna Group runs two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, care services) and Cigna Healthcare (commercial medical plans, international health), serving 185 million customer relationships. Revenue comes from pharmacy processing fees, insurance premiums, drug dispensing margins, and ASO fees across more than 30 markets as of December 31, 2025.

Related stocks: OSCR (Oscar Health, Inc.) · CVS (CVS Health Corporation) · HUM (Humana Inc.) · CNC (Centene Corporation) · ELV (Elevance Health, Inc.)
Home Stocks CI

Latest news

Latest News

Benzinga7d ago
Benzinga13d ago
Benzinga20d ago
Benzinga24d ago
Benzinga24d agoAnalyst
Benzinga26d agoAnalyst
Benzinga27d ago
Benzinga27d ago
Benzinga34d agoEarnings
Benzinga41d ago
Benzinga43d agoAnalyst
Benzinga45d ago
Benzinga45d agoAnalyst
Benzinga45d agoAnalyst
Benzinga45d agoAnalyst
Benzinga46d ago
Benzinga46d agoEarnings
Benzinga47d agoEarnings
Benzinga47d agoEarnings
Benzinga47d ago
Loading more...